IDEAYA Biosciences (FRA:30J) Debt-to-Revenue : 0.69 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

IDEAYA Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.29 Mil. IDEAYA Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €18.02 Mil. IDEAYA Biosciences's annualized Revenue for the quarter that ended in Dec. 2024 was €26.74 Mil. IDEAYA Biosciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.68.

IDEAYA Biosciences Debt-to-Revenue Historical Data

The historical data trend for IDEAYA Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Debt-to-Revenue Chart

IDEAYA Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

0.34

0.19

0.07

0.12

2.74

IDEAYA Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															0.18	N/A	N/A	N/A	0.69

Competitive Comparison of IDEAYA Biosciences's Debt-to-Revenue

For the Biotechnology subindustry, IDEAYA Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEAYA Biosciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

IDEAYA Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

IDEAYA Biosciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.285	+	18.024)	/	6.685
	=	2.74

IDEAYA Biosciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.285	+	18.024)	/	26.74
	=	0.68

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

IDEAYA Biosciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEAYA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (FRA:30J) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

IDYA:USA

Address

5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.ideayabio.com

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

IDEAYA Biosciences Headlines

No Headlines